Navigation Links
Cytopia Lodges IND for JAK2 Inhibitor CYT387
Date:6/22/2009

MELBOURNE, Australia, June 22 /PRNewswire/ -- Cytopia Ltd (ASX: CYT) announced today that it has filed an Investigational New Drug Application (IND) with the US Food and Drug Administration (FDA) for its novel, potent orally active JAK2 inhibitor CYT387.

Following FDA review, the company intends to commence a Phase I/II trial for CYT387 in patients with myelofibrosis, a serious progressive and chronic condition where scar tissue develops in the bone marrow. CYT387 is expected to be the second Cytopia developed drug candidate in clinical studies and the first trialled in the United States, with the anticancer

vascular disrupting agent CYT997 now in Phase II clinical studies in Australia.

Over-activity of the JAK2 enzyme is implicated in a variety of haematological conditions known as the myeloproliferative disorders (MPDs). This suite of conditions includes myelofibrosis, polycythemia vera and essential thrombocythemia. Cytopia has demonstrated that CYT387 inhibits the overactive JAK2 enzyme in an invivo preclinical model and in cells from patients with MPDs. This data suggests that the compound may exert a profound effect on the human disease.

Myelofibrosis results in a compromised ability of patients to produce sufficient blood cells and a reliance on organs other than the bone marrow, including the liver and spleen, to produce cells. Typical symptoms include an enlarged spleen and progressive anemia and poor overall survival.

"The filing of an IND for CYT387 is the culmination of a comprehensive preclinical development effort by the Cytopia Drug Development team," said Mr Andrew Macdonald, CEO of Cytopia. "Our deep knowledge of the JAK2 target has been integral to the design of this drug and the program is significantly bolstered by the intellectual property we hold over the JAK2 target."

The clinical utility of CYT387 is also expected to have broader applicability in diseases driven by disregulated JAK2 signalling, including some cancers and various inflammatory conditions. Cytopia is

exploring the utility of CYT387 in these conditions.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the development of new drugs to treat cancer and other diseases. Cytopia conducts its drug development through subsidiaries based in Australia

and USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The lead program for the company is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, currently being trialed in Phase II clinical studies. This compound is delivered orally as well as intravenously. Cytopia also has built on its range of JAK and other kinase inhibitors with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders and cancer, expected to enter Phase I clinical studies in 2009.


'/>"/>
SOURCE Cytopia Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cytopia To Present Data on FMS Program With Anticancer Potential
2. Cytopia Commences Phase II Cancer Drug Study
3. Potent metastasis inhibitor identified
4. Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
5. Cylene to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at BIO Conference
6. For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018
7. Video: Novartis Receives Approval From FDA to Market Prevacid(R) 24HR as First and Only OTC Proton Pump Inhibitor in Original Prescription Formulation
8. SCAI Statement on A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study
9. Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology
10. Potential lung disease biomarkers yield clues to COX-2 inhibitor side effects
11. Experimental insulin-like growth factor receptor inhibitor reduced pancreatic cancer growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... ... its sugar-free alternative VW+ 002. The drinks have been produced in collaboration with ... to perform during your workout. , After a successful launch in Sweden last ...
(Date:1/20/2017)... ... 2017 , ... D R Burton Healthcare Products LLC, makers ... in a study indicating superior performance against competitive products in secretion clearance. ... Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the winter issue ...
(Date:1/20/2017)... ... ... “God's Miracle Man: Against All Odds”: an inspiring affirmation of God’s work. “God's ... Tucker, son of Minister Delores Pinnock and a Jamaican native who lives in Kingston ... sitting up in bed, I felt a pounding headache. It was like a drum ...
(Date:1/19/2017)... ... ... the cold weather here, many people will have to clear snow with snow blowers or ... snow, but they can be dangerous when used incorrectly. That’s why Amica Insurance ... use of snow blowers:, , When removing wet snow or debris ...
(Date:1/19/2017)... ... January 19, 2017 , ... Cosmetic Town, an online ... procedures in order to make it easier for their readers to get the information ... they impact as well as the techniques used on those particular areas. , “We ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... 2017 Wells Specialty Pharmacy announces the acquisitions and ... in Winter Park, Florida and Pharm-EZ ... Operations have been consolidated into the 3796 Howell Branch Road ... announce that Chad Tomlinson , former Vice President of ... immediately. Mr. Tomlinson is a Graduate of Florida State University ...
(Date:1/19/2017)... 19, 2017 Report Details What ... areas are going to grow at the fastest rates? ... assessing data, trends, opportunities and prospects. Our 190-page ... most lucrative areas in the industry and the future ... sales across the all the major categories of the ...
(Date:1/19/2017)... NEW YORK , Jan. 19, 2017 ... studies the current and future scenario of the global ... for rising opioid consumption. Severe chronic constipation is a ... resistance to traditional laxatives. Hence, novel targeted therapy has ... of OIC sufferers, launch of targeted medicines, and growing ...
Breaking Medicine Technology: